An HIV drug that redirects immune cell traffic appears to significantly reduce the dangerous complication graft-versus-host disease (GvHD) in blood cancer patients following allogeneic stem cell transplantation, according to new research from the Perelman School of Medicine at the University of Pennsylvania.  Standard GvHD treatments suppress the immune system, reducing—but not eliminating—the risk of developing [Sign in to read the full article...]